Table 4 Multivariate analysis for recurrence-free survival and distant recurrence-free survival

Model 1*

6.72 (1.97–22.90)

0.078

4.06 (0.85–19.29)

T3–4 stage (vs. T1 stage)

14.30 (3.65–56.12)

0.002

15.96 (2.90–87.91)

N1–3 stage (vs. N0 stage)

1.66 (0.78–3.50)

0.849

1.11 (0.39–3.17)

BLR (1.0 increase)

11.04 (1.96–62.15)

0.001

34.16 (4.05–288.23)

Model 2**

Negative ER (vs. positive)

4.55 (1.73–12.00)

0.003

8.71 (2.58–64.19)

Negative PR (vs. positive)

1.36 (0.51–3.58)

0.518

0.52 (0.07–3.81)

Triple negative tumor

1.34 (0.54–3.30)

0.273

1.92 (0.60–6.18)

BLR (1.0 increase)

51.41 (9.35–282.74)

< 0.001

162.31 (20.73–1271.00)

Model 3***

PLR (1.0 increase)

1.00 (1.00–1.01)

0.030

1.01 (1.00–1.01)

BLR (1.0 increase)

18.08 (3.52–92.80)

< 0.001

61.13 (8.58–435.36)

Model 4*

Maximum SUV (1.00 increase)

1.05 (1.01–1.10)

0.183

1.05 (0.98–1.12)

TLG (1.00 g increase)

1.01 (1.00–1.01)

0.010

1.01 (1.00–1.01)

BLR (1.0 increase)

23.16 (4.51–119.06)

< 0.001

62.59 (8.76–447.36)

Model 5**

T2 stage (vs. T1 stage)

6.16 (1.82–20.88)

0.136

3.25 (0.69–15.30)

T3–4 stage (vs. T1 stage)

11.09 (2.90–42.32)

0.007

9.49 (1.85–48.68)

Negative ER (vs. positive)

2.90 (1.44–5.86)

0.001

4.88 (1.86–12.82)

TLG (1.00 g increase)

1.00 (1.00–1.01)

0.484

1.00 (1.00–1.00)

BLR (1.0 increase)

16.38 (2.94–91.14)

0.001

80.45 (8.87–729.86)